类固醇5a-还原酶Ⅱ基因89位点多态性与亚洲男性前列腺癌易感性的Meta分析

Steroid 5 - a - reductase type 2 gene 89 polymorphism and genetic susceptibility to prostate cancer in Asian man： a metaan-alysis

目的探讨类固醇5a-还原酶Ⅱ（SRDSa2）基因89位点多态性与亚洲男性前列腺癌易感性的关系。方法检索PubMed、中国知网、万方、维普数据库，获取SRD5a2基因89位点多态性与亚洲男性前列腺癌易感性的病例一对照研究。以前列腺癌组与对照组人群基因型分布的OR值为效应指标，采用固定或随机效应模型进行合并分析，并进行偏倚评估，应用Stata10．0软件进行统计学处理。结果共纳入文献10篇，病例一对照研究8项，累计前列腺癌病例1141例，对照1423例。总的来说，与等位基因V相比，L等位基因合并的OR（95％CI）为0．96（0．91—1．02）；与野生基因型VV相比，LL、LV和LL＋LV基因型合并的OR（95％CI）分别为0．94（0．84～1．04）、0．96（0．89～1．03）和0．97（0．92～1．02）；隐性模型（LLVS．LV＋VV）合并的OR（95％CI）为0．95（0．84～1．09）。而在对照来源于医院的亚分组中，我们发现携带LV基因型的个体与携带VV基因型的个体相比，其患前列腺癌的风险降低合并的OR（95％CI）为0．86（0．75～1．00）。结论总体上，SRD5a2基因89位点变异与亚洲男性个体患前列腺癌的易感性无关，而在在对照来源为医院的研究中，能降低亚洲男性患前列腺癌的风险性。

Objectives To investigate the relationship between steroid 5 - a - reductase type 2 （SRD5a2） gene V89L polymorphism and genetic susceptibility to prostate cancer in Asian man. Methods PubMed, China National Knowledge Infrastructure （ CNKI）, Wanfang database and Weipu database were searched for published case -control studies investigating the association between SRD5a2 V89L polymorphism and susceptibility to prostate cancer in Asian man. The odds ratio was calculated to evaluate the genotypes of prostate cancer patients and controls subjects. Fixed or random effect models were selected for pooled odds ratio calculation. Publication bias was assessed. All statistical analysis was conducted with Stata 10.0 software. Results A total of eight case - control studies involving 1141 prostate cancer patients and 1423 controls were analyzed in our study. Overall, compared with the V allele, the pooled odds ratio （OR） [ and 95% confidence interval （CI） ] for L allele was 0. 96 （0.91 - 1. 01 ） ; compared with the wide - type genotype （ homozygote VV）, the pooled OR （95% CI） for LL, LV and LL ＋ LV genotypes was 0.94 （0.84 - 1.04 ）, 0.95 （ 0.89 - 1.02 ） and 0.96 （ 0.92 - 1. 01 ）, respectively. In the recessive genetic model, the pooled OR （95% CI） was 0.96 （0.84 - 1.09 ）. However, in the source of control subgroup, individuals carried LV genotype may decrease prostate cancer risk compared to VV genotype. Conclusions Totally, SRD5a2 V89L polymorphism may not be associated with susceptibility of prostate cancer in Asian man, however, in the source of control subgroup, a decreased risk was detected between this polymorphism and prostate cancer.